{"protocolSection":{"identificationModule":{"nctId":"NCT04984577","orgStudyIdInfo":{"id":"NJYK-CPEDRV-II"},"organization":{"fullName":"Nanjing Yoko Biomedical Co., Ltd.","class":"INDUSTRY"},"briefTitle":"Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke","officialTitle":"Phase Ⅲ Trial of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke -- a Multi-center, Randomized, Double-blind, Parallel, Multi-doses and Active-controlled Study"},"statusModule":{"statusVerifiedDate":"2021-07","overallStatus":"UNKNOWN","lastKnownStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-09","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2022-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-07-29","studyFirstSubmitQcDate":"2021-07-29","studyFirstPostDateStruct":{"date":"2021-07-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-07-29","lastUpdatePostDateStruct":{"date":"2021-07-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Nanjing Yoko Biomedical Co., Ltd.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner. The study is also to examine the safety of compound Edaravone Injection for the AIS patients."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":240,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Compound Edaravone Injection-Low dose","type":"EXPERIMENTAL","interventionNames":["Drug: Compound Edaravone Injection-Low dose"]},{"label":"Compound Edaravone Injection-High dose","type":"EXPERIMENTAL","interventionNames":["Drug: Compound Edaravone Injection-High dose"]},{"label":"Edaravone Injection","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Edaravone Injection"]},{"label":"Placebo Injection","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo injection"]}],"interventions":[{"type":"DRUG","name":"Compound Edaravone Injection-Low dose","description":"Compound Edaravone Injection 30mg/dose (Edaravone 30mg, Taurine 600 mg), one dose every 12 hours, continue for 14 days","armGroupLabels":["Compound Edaravone Injection-Low dose"]},{"type":"DRUG","name":"Compound Edaravone Injection-High dose","description":"Compound Edaravone Injection 50mg/dose (Edaravone 50mg, Taurine 1000 mg), one dose every 12 hours, continue for 14 days","armGroupLabels":["Compound Edaravone Injection-High dose"]},{"type":"DRUG","name":"Edaravone Injection","description":"Edaravone Injection 30mg/dose, one dose every 12 hours, continue for 14 days","armGroupLabels":["Edaravone Injection"]},{"type":"DRUG","name":"Placebo injection","description":"Placebo injection, one dose every 12 hours, continue for 14 days","armGroupLabels":["Placebo Injection"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The proportion of patients with mRS ≤1 on day 90","timeFrame":"day 90"}],"secondaryOutcomes":[{"measure":"Changes of NIHSS score from baseline on day 14","timeFrame":"day 14"},{"measure":"The proportion of patients with mRS ≤2 on day 90","timeFrame":"day 90"},{"measure":"The proportion of patients with NIHSS score 0-1 (including motor function) on day 14, 30, 90","timeFrame":"day 14, 30, 90"},{"measure":"The proportion of patients with ADL-BI ≥95 on day 14, 30, 90","timeFrame":"day 14, 30, 90"},{"measure":"EQ-5D score on day 90","timeFrame":"day 90"},{"measure":"Ordinal Distribution of mRS on day 90","timeFrame":"day 90"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hospitalized patients, diagnosed of ischemic stroke;\n* Onset of stroke is less than or equal to 48 hours;\n* There are clear signs of neurological deficit: 4≤NIHSS score≤24, and also, the sum of NIHSS score for the upper limb and the lower limb is greater than or equal to 2;\n* Patients signed written inform consent\n\nExclusion Criteria:\n\n* Cranial CT scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage;\n* Iatrogenic stroke;\n* Severe disturbance of consciousness: NIHSS category 1a for consciousness is greater than 1；\n* The mRS score prior to this onset is greater than 1;\n* Transient ischemic attack (TIA);\n* SBP after blood pressure control is still greater than or equal to 220 mmHg, or DBP after blood pressure control is still greater than or equal to 120 mmHg;\n* Patients with severe mental disorders and dementia;\n* ALT or AST is greater than 2.0×ULN; Serum Creatinine (SCr) is greater than 1.5×ULN or Creatinine Clearance (CrCl) is less than 50 ml/min;\n* Therapeutic neuroprotective agents have been applied after onset of stroke, including commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam, butyl benzene peptides, Urinary Kallidinogenase;\n* Thrombectomy or interventional therapy has been applied or planned after this onset;\n* Patients with malignant tumors or receiving concurrent antitumor treatment;\n* Patients with severe systemic disease, life expectancy is less than 90 days;\n* Allergic to edaravone , taurine or related excipients;\n* Pregnant or lactating women;\n* Have major surgery within 4 weeks before enrollment and not recovered enough to start the study;\n* Participated in other clinical studies within 30 days before randomization;\n* The investigators consider the patients are not suitable for this trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Beijing Tiantan Hospital，Capital Medical University","city":"Beijing","country":"China","contacts":[{"name":"Yongjun Wang, professor","role":"CONTACT","phone":"13911172565","email":"yongjunwang111@aliyun.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077553","term":"Edaravone"}],"ancestors":[{"id":"D000016166","term":"Free Radical Scavengers"},{"id":"D000000975","term":"Antioxidants"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M1831","name":"Edaravone","asFound":"Lay","relevance":"HIGH"},{"id":"M3982","name":"Antioxidants","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"T19","name":"Taurine","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}